Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C virus: a critical appraisal of approaches to therapy.
Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Nelson DR, et al. Among authors: jensen dm. Clin Gastroenterol Hepatol. 2009 Apr;7(4):397-414; quiz 366. doi: 10.1016/j.cgh.2008.11.016. Epub 2008 Nov 21. Clin Gastroenterol Hepatol. 2009. PMID: 19114127 Review. No abstract available.
Hepatitis C virus: a critical appraisal of new approaches to therapy.
Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Nelson DR, et al. Among authors: jensen dm. Hepat Res Treat. 2012;2012:138302. doi: 10.1155/2012/138302. Epub 2012 Oct 8. Hepat Res Treat. 2012. PMID: 23094146 Free PMC article.
The FDA, bridging data, and hepatitis C.
Fried MW, Jensen DM. Fried MW, et al. Among authors: jensen dm. Hepatology. 2013 Mar;57(3):875-7. doi: 10.1002/hep.26177. Hepatology. 2013. PMID: 23456679 No abstract available.
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Nelson DR, et al. Among authors: jensen dm. Ann Hepatol. 2012 Jan-Feb;11(1):15-31. Ann Hepatol. 2012. PMID: 22166557 Free PMC article. Clinical Trial.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lawitz E, et al. Lancet Infect Dis. 2013 May;13(5):401-8. doi: 10.1016/S1473-3099(13)70033-1. Epub 2013 Mar 15. Lancet Infect Dis. 2013. PMID: 23499158 Clinical Trial.
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico C, Fried M, Jensen D, Brown RS Jr, Horwith G, Brundage R, Lok A. Dickson RC, et al. Liver Transpl. 2006 Jan;12(1):124-33. doi: 10.1002/lt.20582. Liver Transpl. 2006. PMID: 16382463 Free article. Clinical Trial.
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S; HALLMARK-QUAD Study Team. Jensen D, et al. J Hepatol. 2015 Jul;63(1):30-7. doi: 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19. J Hepatol. 2015. PMID: 25703086 Clinical Trial.
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Zeuzem S, et al. Among authors: jensen dm. J Hepatol. 2003 Jul;39(1):106-11. doi: 10.1016/s0168-8278(03)00187-9. J Hepatol. 2003. PMID: 12821051 Clinical Trial.
441 results